This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 50/4/762    most recent HYPERTENSIONAHA.107.094987v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carvalho, M. B.L. Articles by Santos, R. A.S. Search for Related Content PubMed PubMed Citation Articles by Carvalho, M. B.L. Articles by Santos, R. A.S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Cardiovascular Pharmacology ACE/Angiotension receptors Endothelium/vascular type/nitric oxide

(Hypertension. 2007;50:762.)
© 2007 American Heart Association, Inc.

XVIIth Scientific Meeting of the Inter-American Society of Hypertension

Evidence for Mas-Mediated Bradykinin Potentiation by the Angiotensin-(1-7) Nonpeptide Mimic AVE 0991 in Normotensive Rats

Mariana B.L. Carvalho; Fernanda V. Duarte; Raphael Faria-Silva; Beatrix Fauler; Leonor T. da Mata Machado; Renata D. de Paula; Maria J. Campagnole-Santos; Robson A.S. Santos

From the Laboratory of Hypertension, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

Correspondence to Robson A.S. Santos, Laboratory of Hypertension, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901 Brazil. E-mail marrob{at}dedalus.lcc.ufmg.br

We evaluated the effect of the nonpeptide mimic of angiotensin (Ang)-(1-7), AVE 0991, on the hypotensive effect of bradykinin (BK). Increasing doses of intra-arterial or intravenous BK were administered before and 30 minutes after the beginning of AVE 0991 infusion. The effect of AVE 0991 on plasma Ang-converting enzyme activity was tested using Hip-His-Leu as the substrate. The interaction of AVE 0991 with Ang-converting enzyme in vivo was tested by determining its effect on the pressor action of Ang I or Ang II. AVE 0991 produced a significant and similar potentiation of intra-arterial or intravenous bradykinin. AVE 0991 did not inhibit plasma Ang-converting enzyme activity in vitro or the pressor effect of Ang I in vivo. N^W-nitro-L-arginine methyl ester or D-Ala⁷-Ang-(1-7) administration abolished the BK potentiating effect of AVE 0991. We further examined the BK-potentiating effect of AVE 0991, evaluating its effect on NO production in rabbit endothelial cells. The NO release was measured using the 4-amino-5-methylamino-2'-7'-difluorofluorescein diacetate. A synergistic effect of AVE 0991 and BK on NO release was observed. These results suggest that AVE 0991 potentiates bradykinin through an Ang-converting enzyme–independent, NO-dependent receptor Mas-mediated mechanism. This effect may contribute to the improvement of endothelial function by AVE 0991 in vivo.

Key Words: bradykinin • angiotensin (1-7) • AVE 0991 • NO • endothelial function

This article has been cited by other articles:

				M. J. Soler, J. Wysocki, and D. Batlle Angiotensin-converting enzyme 2 and the kidney Exp Physiol, May 1, 2008; 93(5): 549 - 556. [Abstract] [Full Text] [PDF]